Original source: https://www.investing.com/news/stock-market-news/novo-nordisk-makes-impairment-loss-of-816-million-in-q2-3497684
Novo Nordisk ends kidney disease trial, books $816 million impairment in Q2
Tweet on Twitter
Share on Facebook
Google+
Pinterest